Home The Word Brain	My Amedeo FAQ Privacy About	Flying Publisher
	OLIENA Language recovery after stroke App | Video | PDF (278 pp) | Web

Drug Resistance

Free Subscription Articles published in AIDS Retrieve available abstracts of 35 articles: HTML format Text format

Single Articles

October 2017
1. MENZA TW, Billock R, Samoff E, Eron JJ, et al
   Pretreatment integrase strand transfer inhibitor resistance in North Carolina from 2010-2016.
   AIDS. 2017;31:2235-2244.
   PubMed     Text format     Abstract available
   
   
   August 2017
2. POPPE LK, Chunda-Liyoka C, Kwon EH, Gondwe C, et al
   HIV drug resistance in infants increases with changing prevention of mother-to-child transmission regimens.
   AIDS. 2017;31:1885-1889.
   PubMed     Text format     Abstract available
   
   
   June 2017
3. GATANAGA H, Brumme ZL, Adland E, Reyes-Teran G, et al
   Potential for immune-driven viral polymorphisms to compromise antiretroviral-based pre-exposure prophylaxis for prevention of HIV-1 infection.
   AIDS. 2017 Jun 23. doi: 10.1097/QAD.0000000000001575.
   PubMed     Text format     Abstract available
   
   
   April 2017
4. INZAULE SC, Hamers RL, Mukui I, Were K, et al
   Emergence of untreatable, multidrug-resistant HIV-1 in patients failing second-line therapy in Kenya.
   AIDS. 2017 Apr 10. doi: 10.1097/QAD.0000000000001500.
   PubMed     Text format     Abstract available
   
   
   
5. LEPIK KJ, Harrigan PR, Yip B, Wang L, et al
   Emergent drug resistance with integrase strand transfer inhibitor-based regimens: Incidence and risk factors.
   AIDS. 2017 Apr 3. doi: 10.1097/QAD.0000000000001494.
   PubMed     Text format     Abstract available
   
   
   March 2017
6. KANTHULA R, Rossouw T, Feucht UD, Van Dyk G, et al
   Persistence of HIV-drug-resistance among South African Children given Nevirapine to Prevent Mother-to-Child-Transmission.
   AIDS. 2017 Mar 15. doi: 10.1097/QAD.0000000000001446.
   PubMed     Text format     Abstract available
   
   
   January 2017
7. NEWSUM AM, Ho CK, Lieveld FI, van de Laar TJ, et al
   The hepatitis C virus nonstructural protein 3 Q80K polymorphism is frequently detected and transmitted among HIV-infected MSM in the Netherlands.
   AIDS. 2017;31:105-112.
   PubMed     Text format     Abstract available
   
   
   November 2016
8. KUNKEL A, Crawford FW, Shepherd J, Cohen T, et al
   Benefits of continuous isoniazid preventive therapy may outweigh resistance risks in a declining tuberculosis/HIV coepidemic.
   AIDS. 2016;30:2715-2723.
   PubMed     Text format     Abstract available
   
   
   September 2016
9. MURI L, Gamell A, Ntamatungiro AJ, Glass TR, et al
   Development of HIV drug resistance and therapeutic failure in children and adolescents in rural tanzania - an emerging public health concern.
   AIDS. 2016.
   PubMed     Text format     Abstract available
   
   
   
10. VILLABONA-ARENAS CJ, Vidal N, Guichet E, Serrano L, et al
    In-depth analysis of HIV-1 drug resistance mutations in HIV-infected individuals failing first-line regimens in West and Central Africa.
    AIDS. 2016.
    PubMed     Text format     Abstract available
    
    
    June 2016
11. OLIVEIRA M, Ibanescu RI, Pham HT, Brenner B, et al
    The M184I/V and K65R nucleoside resistance mutations in HIV-1 prevent the emergence of resistance mutations against dolutegravir.
    AIDS. 2016.
    PubMed     Text format     Abstract available
    
    
    April 2016
12. MUSIIME V, Kasirye P, Naidoo-James B, Nahirya-Ntege P, et al
    Once versus twice daily abacavir and lamivudine in African children: The randomised controlled ARROW Trial.
    AIDS. 2016.
    PubMed     Text format     Abstract available
    
    
    
13. CHUNG MH, Silverman R, Beck IA, Yatich N, et al
    Increasing HIV-1 pre-treatment drug resistance among antiretroviral-naive adults initiating treatment between 2006 and 2014 in Nairobi, Kenya.
    AIDS. 2016.
    PubMed     Text format     Abstract available
    
    
    January 2016
14. CASADELLA M, Noguera-Julian M, Sunpath H, Gordon M, et al
    Treatment options after virological failure of first-line tenofovir-based regimens in South Africa: an analysis by deep sequencing.
    AIDS. 2016.
    PubMed     Text format     Abstract available
    
    
    
15. WEIS JF, Baeten JM, McCoy CO, Warth C, et al
    Preexposure prophylaxis-selected drug resistance decays rapidly after drug cessation.
    AIDS. 2016;30:31-5.
    PubMed     Text format     Abstract available
    
    
    
16. VAN LUNZEN J, Antinori A, Cohen CJ, Arribas JR, et al
    Rilpivirine vs. efavirenz-based single-tablet regimens in treatment-naive adults: week 96 efficacy and safety from a randomized phase 3b study.
    AIDS. 2016;30:251-9.
    PubMed     Text format     Abstract available
    
    
    November 2015
17. KONOU AA, Dagnra AY, Vidal N, Salou M, et al
    Alarming rates of virological failure and drug resistance in patients on long-term antiretroviral treatment in routine HIV clinics in Togo.
    AIDS. 2015;29:2527-30.
    PubMed     Text format     Abstract available
    
    
    September 2015
18. WINAND R, Theys K, Eusebio M, Aerts J, et al
    Assessing transmissibility of HIV-1 drug resistance mutations from treated and from drug-naive individuals.
    AIDS. 2015;29:2045-52.
    PubMed     Text format     Abstract available
    
    
    
19. MOURAD R, Chevennet F, Dunn DT, Fearnhill E, et al
    A phylotype-based analysis highlights the role of drug-naive HIV-positive individuals in the transmission of antiretroviral resistance in the UK.
    AIDS. 2015;29:1917-25.
    PubMed     Text format     Abstract available
    
    
    
20. OLIVEIRA M, Mesplede T, Moisi D, Ibanescu RI, et al
    The dolutegravir R263K resistance mutation in HIV-1 integrase is incompatible with the emergence of resistance against raltegravir.
    AIDS. 2015.
    PubMed     Text format     Abstract available
    
    
    August 2015
21. PETERSON CW, Haworth KG, Polacino P, Huang ML, et al
    Lack of viral control and development of combination antiretroviral therapy escape mutations in macaques after bone marrow transplantation.
    AIDS. 2015;29:1597-606.
    PubMed     Text format     Abstract available
    
    
    July 2015
22. LOPES GI, Coelho LP, Hornke L, Volpato AP, et al
    Transmission of a multidrug-resistant HIV-1 from an occupational exposure, in Sao Paulo, Brazil.
    AIDS. 2015;29:1580-3.
    PubMed     Text format    
    
    
    
23. CASADELLA M, Manzardo C, Noguera-Julian M, Ferrer E, et al
    Clinical value of ultradeep HIV-1 genotyping and tropism testing in late presenters with advanced disease.
    AIDS. 2015;29:1493-504.
    PubMed     Text format     Abstract available
    
    
    
24. OLSON SC, Ngo-Giang-Huong N, Beck I, Deng W, et al
    Resistance detected by pyrosequencing following zidovudine monotherapy for prevention of HIV-1 mother-to-child-transmission.
    AIDS. 2015;29:1467-71.
    PubMed     Text format     Abstract available
    
    
    
25. MESPLEDE T, Quashie PK, Hassounah S, Osman N, et al
    The R263K substitution in HIV-1 subtype C is more deleterious for integrase enzymatic function and viral replication than in subtype B.
    AIDS. 2015;29:1459-66.
    PubMed     Text format     Abstract available
    
    
    
26. HARPER KN
    New study suggests resistance testing may not be best use of resources for HIV treatment programmes in low-income settings.
    AIDS. 2015;29:N7.
    PubMed     Text format    
    
    
    
27. NELSON JA, Fokar A, Hudgens MG, Compliment KJ, et al
    Frequent nevirapine resistance in infants infected by HIV-1 via breastfeeding while on nevirapine prophylaxis: results of the Breastfeeding, Antiretrovirals and Nutrition study.
    AIDS. 2015.
    PubMed     Text format     Abstract available
    
    
    
28. LIMA VD, Reuter A, Harrigan PR, Lourenco L, et al
    Initiation of antiretroviral therapy at high CD4+ cell counts is associated with positive treatment outcomes.
    AIDS. 2015.
    PubMed     Text format     Abstract available
    
    
    June 2015
29. ALESSANDRI-GRADT E, Morgand M, Delaugerre C, Peytavin G, et al
    HIV-1 group O resistance pathway with raltegravir is similar to HIV-1 group M.
    AIDS. 2015;29:1271-3.
    PubMed     Text format    
    
    
    
30. BONADIES G, Maraolo AE, Tambaro O, Palmiero G, et al
    Dolutegravir: successful experience in a challenging patient.
    AIDS. 2015;29:1269-71.
    PubMed     Text format    
    
    
    
31. PERE H, Roques P, Talla F, Meillo H, et al
    Sustained virological failure in Cameroonese patient infected by HIV-1 group N evidenced by sequence-based genotyping assay.
    AIDS. 2015;29:1267-9.
    PubMed     Text format    
    
    
    
32. THIO CL, Smeaton L, Hollabaugh K, Saulynas M, et al
    Comparison of HBV-active HAART regimens in an HIV-HBV multinational cohort: outcomes through 144 weeks.
    AIDS. 2015;29:1173-82.
    PubMed     Text format     Abstract available
    
    
    
33. SCHULTZE A, Phillips AN, Paredes R, Battegay M, et al
    HIV resistance testing and detected drug resistance in Europe.
    AIDS. 2015.
    PubMed     Text format     Abstract available
    
    
    May 2015
34. ABECASIS AB, van Laethem K, Theys K
    Lack of evidence for the selection of E138 mutations by first-generation non-nucleoside reverse transcriptase inhibitors in patients infected with HIV-1 non-B subtypes.
    AIDS. 2015;29:987-8.
    PubMed     Text format    
    
    
    April 2015
35. LI JZ, Smith DM, Mellors JW
    The critical roles of treatment interruption studies and biomarker identification in the search for an HIV cure.
    AIDS. 2015.
    PubMed     Text format    
    
    

Thank you for your interest in scientific medicine.

AMEDEO Drug Resistance is free of charge. This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim. Design: